Implications of ICS prescription duration on asthma outcomes

The study aims at assessing the relation between prescription patterns (unchanged vs increased script duration) and (i) cumulative time covered (MPR, medication possession ratio) and (ii) clinical outcomes over a one-year outcome period, in patients receiving ICS with any script duration during the baseline year.

Lead Investigator:

Lead Investigator

Professor David Price, Professor of Primary Care Respiratory Medicine and RiRL Director

Research Team:

  • Nicolas Roche
  • Dirkje Postma
  • Richard Martin
  • Eliot Israel
  • Gene Colice
  • Rupert Jones
  • Catherine Hutton
  • Dr Arjun Jain
  • Vicky Thomas
  • Derek Skinner

Status: Active Study

Support:

Registration:

Documents and Publications

Protocol

Abstracts

Presentations

Final Publications

Additional Material

 

Zoe Mitchell

 

Leave a Reply

Your email address will not be published. Required fields are marked *